Mucka Patrick
G. Kern Joseph
Feng Hui
1. Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104-6160, USA
2. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA
3. Departments of Pharmacology and Medicine, The Center for Cancer Research, Section of Hematology and Medical Oncology, Boston University School of Medicine, Boston, MA 02118, USA
4. Program in Biomedical Sciences, Boston University School of Medicine, Boston, MA 02118, USA
Funds: This work was supported by a young investigator award from the Leukemia Research Foundation, a Ralph Edwards Career Development Professorship from Boston University, a Scholar grant from the St. Baldrick's Foundation, an ignition award from Boston University, a clinical translational institute pilot from the National Institute of Health (1UL1TR001430), an institutional grant (IRG-72-001-36-IRG) from the American Cancer Society, and a grant from the Mary Kay Ash Foundation to H.F., a young investigator award from the Alex Lemonade Stand to N.M.A., P.M. acknowledges training support through T32GM008541 from the National Institutes of Health.
More InformationCorresponding author: Hui Feng, huifeng@bu.edu
Received Date: 2017-05-03
Accepted Date:2017-06-26
Publish Date:2018-01-01
Abstract
Abstract
The tricarboxylic acid (TCA) cycle is a central route for oxidative phosphorylation in cells, and fulfills their bioenergetic, biosynthetic, and redox balance requirements. Despite early dogma that cancer cells bypass the TCA cycle and primarily utilize aerobic glycolysis, emerging evidence demonstrates that certain cancer cells, especially those with deregulated oncogene and tumor suppressor expression, rely heavily on the TCA cycle for energy production and macromolecule synthesis. As the field progresses, the importance of aberrant TCA cycle function in tumorigenesis and the potentials of applying small molecule inhibitors to perturb the enhanced cycle function for cancer treatment start to evolve. In this review, we summarize current knowledge about the fuels feeding the cycle, effects of oncogenes and tumor suppressors on fuel and cycle usage, common genetic alterations and deregulation of cycle enzymes, and potential therapeutic opportunities for targeting the TCA cycle in cancer cells. With the application of advanced technology and in vivo model organism studies, it is our hope that studies of this previously overlooked biochemical hub will provide fresh insights into cancer metabolism and tumorigenesis, subsequently revealing vulnerabilities for therapeutic interventions in various cancer types.Keywords: glutaminolysis,
the TCA cycle,
cancer metabolism,
glycolysis
PDF全文下载地址:
http://www.protein-cell.org/article/exportPdf?id=0cc6cf60-c1b6-4457-84e8-99b94d0a5851&language=en
